menu
    • menu
    [{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Bortezomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Takeda Pharmaceutical | Multiple Myeloma Research Consortium","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ixazomib Citrate","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Takeda Pharmaceutical | Multiple Myeloma Research Consortium","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Takeda Pharmaceutical | Multiple Myeloma Research Consortium"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Regadenoson Monohydrate","moa":"Adenosine A2a receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Astellas Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Washington University School of Medicine \/ Astellas Pharma"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Cantex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Azeliragon","moa":"Advanced glycosylation end product-specific receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Cantex Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Cantex Pharmaceuticals"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Alzheimer's Association | Eli Lilly | National Institute on Aging","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Remternetug","moa":"Amyloid","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Alzheimer's Association | Eli Lilly | National Institute on Aging","highestDevelopmentStatusID":"9","companyTruncated":"Washington University School of Medicine \/ Alzheimer's Association | Eli Lilly | National Institute on Aging"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Alzheimer's Association | Eli Lilly | National Institute on Aging | GHR Foundation | Private Donors","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Remternetug","moa":"Amyloid","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Alzheimer's Association | Eli Lilly | National Institute on Aging | GHR Foundation | Private Donors","highestDevelopmentStatusID":"9","companyTruncated":"Washington University School of Medicine \/ Alzheimer's Association | Eli Lilly | National Institute on Aging | GHR Foundation | Private Donors"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Eli Lilly | F. Hoffmann-La Roche | Alzheimer's Association | National Institute on Aging | Accelerating Medicines Partnership | Eisai Inc | Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Eli Lilly | F. Hoffmann-La Roche | Alzheimer's Association | National Institute on Aging | Accelerating Medicines Partnership | Eisai Inc | Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"9","companyTruncated":"Washington University School of Medicine \/ Eli Lilly | F. Hoffmann-La Roche | Alzheimer's Association | National Institute on Aging | Accelerating Medicines Partnership | Eisai Inc | Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Eli Lilly | F. Hoffmann-La Roche | Alzheimer's Association | National Institute on Aging | Accelerating Medicines Partnership","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Eli Lilly | F. Hoffmann-La Roche | Alzheimer's Association | National Institute on Aging | Accelerating Medicines Partnership","highestDevelopmentStatusID":"9","companyTruncated":"Washington University School of Medicine \/ Eli Lilly | F. Hoffmann-La Roche | Alzheimer's Association | National Institute on Aging | Accelerating Medicines Partnership"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"F. Hoffmann-La Roche | Alzheimer's Association | National Institute on Aging","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ F. Hoffmann-La Roche | Alzheimer's Association | National Institute on Aging","highestDevelopmentStatusID":"9","companyTruncated":"Washington University School of Medicine \/ F. Hoffmann-La Roche | Alzheimer's Association | National Institute on Aging"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Alzheimer's Association | Eisai Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Alzheimer's Association | Eisai Inc","highestDevelopmentStatusID":"10","companyTruncated":"Washington University School of Medicine \/ Alzheimer's Association | Eisai Inc"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"HT-ALZ","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Preclinical","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Washington University School of Medicine \/ Washington University School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Washington University School of Medicine \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"HT-ALZ","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Preclinical","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Washington University School of Medicine \/ Washington University School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Washington University School of Medicine \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"HT-ALZ","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Preclinical","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Hoth Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Washington University School of Medicine \/ Hoth Therapeutics"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Tyrogenex","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors||Platelet-derived growth factor receptor | Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Tyrogenex","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ Tyrogenex"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Xcovery","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Xcovery","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Xcovery"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Xcovery","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Xcovery","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Xcovery"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2021","type":"Inapplicable","leadProduct":"18-F FluorApoTrace","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ AbbVie Inc"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Project Peanut Butter | Kamuzu University of Health Sciences | BALCHEM","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Washington University School of Medicine \/ Project Peanut Butter | Kamuzu University of Health Sciences | BALCHEM","highestDevelopmentStatusID":"1","companyTruncated":"Washington University School of Medicine \/ Project Peanut Butter | Kamuzu University of Health Sciences | BALCHEM"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Theriva Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Ribaxamase","moa":"Beta-lactam antibiotics","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Washington University School of Medicine \/ Washington University School of Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Blinatumomab","moa":"B-lymphocyte antigen CD19 | T cell surface glycoprotein CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Amgen Inc","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Amgen Inc"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Maraviroc","moa":"C-C chemokine receptor type 5","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"Washington University School of Medicine \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Pfizer Inc"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Bristol Myers Squibb | Foundation for Barnes-Jewish Hospital | National Institutes of Health | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"BMS-813160","moa":"C-C chemokine receptor type 5 | C-C chemokine receptor type 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Bristol Myers Squibb | Foundation for Barnes-Jewish Hospital | National Institutes of Health | National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ Bristol Myers Squibb | Foundation for Barnes-Jewish Hospital | National Institutes of Health | National Cancer Institute"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Wugen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"WU-CART-007","moa":"CD7","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Wugen","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Wugen"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Pfizer Inc | Joseph Sanchez Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase III","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Suspension","sponsorNew":"Washington University School of Medicine \/ Pfizer Inc | Joseph Sanchez Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Washington University School of Medicine \/ Pfizer Inc | Joseph Sanchez Foundation"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase III","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Suspension","sponsorNew":"Washington University School of Medicine \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Washington University School of Medicine \/ Pfizer Inc"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Pfizer Inc"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Pfizer Inc | Rising Tide Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Pfizer Inc | Rising Tide Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Pfizer Inc | Rising Tide Foundation"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Pfizer Inc"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Celgene Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Celgene Corporation"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"MCS110","moa":"CSF1R","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"BioLineRx","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2023","type":"Collaboration","leadProduct":"Motixafortide","moa":"||C-X-C chemokine receptor type 4","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Washington University School of Medicine \/ Washington University School of Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"BioLineRx | Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Motixafortide","moa":"C-X-C chemokine receptor type 4","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Washington University School of Medicine \/ BioLineRx | Biogen","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ BioLineRx | Biogen"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"BioLineRx | Arvrmid Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Motixafortide","moa":"C-X-C chemokine receptor type 4","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Washington University School of Medicine \/ BioLineRx | Arvrmid Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ BioLineRx | Arvrmid Pharma"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"BioLineRx","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Motixafortide","moa":"C-X-C chemokine receptor type 4","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ BioLineRx","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ BioLineRx"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ Eli Lilly"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Medical Compression Systems","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Aspirin","moa":"Cyclooxygenase","graph1":"Hematology","graph2":"Phase IV","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Medical Compression Systems","highestDevelopmentStatusID":"11","companyTruncated":"Washington University School of Medicine \/ Medical Compression Systems"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Assertio Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ketorolac Trometamol","moa":"Cyclooxygenase","graph1":"Neurology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Assertio Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Assertio Therapeutics"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"LB Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lb-102","moa":"D2\/D3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Washington University School of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Tilde Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Pyrimethamine","moa":"Dihydrofolate reductase","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Tilde Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Tilde Sciences"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Washington University School of Medicine \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Washington University School of Medicine \/ Merck & Co"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"BioMarin Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2015","type":"Inapplicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ BioMarin Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ BioMarin Pharmaceutical"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Acerta Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Bendamustine Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Acerta Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Acerta Pharma"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"EMD Serono","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA","graph1":"Neurology","graph2":"Phase IV","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Washington University School of Medicine \/ EMD Serono","highestDevelopmentStatusID":"11","companyTruncated":"Washington University School of Medicine \/ EMD Serono"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"CPX-351","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Washington University School of Medicine \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Centers for Medicare and Medicaid Services\/ Coverage and Analysis Group | Therakos | Foundation for Barnes-Jewish Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Methoxsalen","moa":"DNA","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Centers for Medicare and Medicaid Services\/ Coverage and Analysis Group | Therakos | Foundation for Barnes-Jewish Hospital","highestDevelopmentStatusID":"10","companyTruncated":"Washington University School of Medicine \/ Centers for Medicare and Medicaid Services\/ Coverage and Analysis Group | Therakos | Foundation for Barnes-Jewish Hospital"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Johnson & Johnson Innovative Medicine | National Institutes of Health | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2017","type":"Inapplicable","leadProduct":"Decitabine","moa":"DNA (cytosine-5)-methyltransferase 1 | DNA | DNA (cytosine-5)-methyltransferase 3A","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Washington University School of Medicine \/ Johnson & Johnson Innovative Medicine | National Institutes of Health | National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Johnson & Johnson Innovative Medicine | National Institutes of Health | National Cancer Institute"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Taiho Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Decitabine","moa":"DNA (cytosine-5)-methyltransferase 1 | DNA | DNA (cytosine-5)-methyltransferase 3A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Taiho Oncology","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ Taiho Oncology"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"American Society of Clinical Oncology | American Society of Hematology | Gabrielle's Angel Foundation | Leukemia and Lymphoma Society | National Cancer Institute | ImmunityBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Fludarabine Phosphate","moa":"DNA polymerase (alpha\/delta\/epsilon) | Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ American Society of Clinical Oncology | American Society of Hematology | Gabrielle's Angel Foundation | Leukemia and Lymphoma Society | National Cancer Institute | ImmunityBio","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ American Society of Clinical Oncology | American Society of Hematology | Gabrielle's Angel Foundation | Leukemia and Lymphoma Society | National Cancer Institute | ImmunityBio"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Eli Lilly"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Sunesis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Vosaroxin","moa":"DNA topoisomerase II | DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Sunesis Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Sunesis Pharmaceuticals"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Genentech"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Sumitomo Pharma America","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"DSP-0390","moa":"EBP","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Sumitomo Pharma America","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Sumitomo Pharma America"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Cetuximab","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ Pfizer Inc"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Clovis Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Rociletinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Clovis Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Clovis Oncology"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Karyopharm Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Selinexor","moa":"Exportin-1","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Karyopharm Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Karyopharm Therapeutics"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Karyopharm Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2015","type":"Inapplicable","leadProduct":"Selinexor","moa":"Exportin-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Karyopharm Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ Karyopharm Therapeutics"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"MorphoSys | Foundation for Barnes-Jewish Hospital | Swim Across America | Daniel E. Corbin Jr. Lymphoma Fund","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tulmimetostat","moa":"EZH2","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ MorphoSys | Foundation for Barnes-Jewish Hospital | Swim Across America | Daniel E. Corbin Jr. Lymphoma Fund","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ MorphoSys | Foundation for Barnes-Jewish Hospital | Swim Across America | Daniel E. Corbin Jr. Lymphoma Fund"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Chloroquine Phosphate","moa":"Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Washington University School of Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Washington University School of Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Clotfoam","moa":"Fibrin","graph1":"Hematology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Washington University School of Medicine \/ Washington University School of Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Washington University School of Medicine \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"National Institutes of Health | The V Foundation for Cancer Research | National Cancer Institute | ImmunityBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ National Institutes of Health | The V Foundation for Cancer Research | National Cancer Institute | ImmunityBio","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ National Institutes of Health | The V Foundation for Cancer Research | National Cancer Institute | ImmunityBio"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Washington University School of Medicine \/ Novo Nordisk","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Novo Nordisk"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Eli Lilly | National Institute on Minority Health and Health Disparities","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"Glucagon-like peptide 1 receptor | Gastric inhibitory polypeptide receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Washington University School of Medicine \/ Eli Lilly | National Institute on Minority Health and Health Disparities","highestDevelopmentStatusID":"11","companyTruncated":"Washington University School of Medicine \/ Eli Lilly | National Institute on Minority Health and Health Disparities"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"National Cancer Institute | Calithera Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Telaglenastat","moa":"Glutaminase kidney isoform, mitochondrial","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ National Cancer Institute | Calithera Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ National Cancer Institute | Calithera Biosciences"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Genomic Health, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Goserelin Acetate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Genomic Health, Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Genomic Health, Inc."},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Varian Medical Systems","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Leuprolide Acetate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Varian Medical Systems","highestDevelopmentStatusID":"1","companyTruncated":"Washington University School of Medicine \/ Varian Medical Systems"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Aravive","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"AVB-S6-500","moa":"Growth arrest-specific protein 6","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Aravive","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Aravive"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Cantex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"CX-01","moa":"Heparanase","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Washington University School of Medicine \/ Cantex Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Cantex Pharmaceuticals"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Molecular Templates","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2021","type":"Inapplicable","leadProduct":"89-Zr Trastuzumab","moa":"HER2","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Washington University School of Medicine \/ Molecular Templates","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Molecular Templates"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Romidepsin","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Epizyme","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Epizyme","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Epizyme"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Raltegravir Potassium","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Merck & Co"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Cue Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"CUE-101","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Cue Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Cue Biopharma"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"NeoImmuneTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efineptakin Alpha","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Washington University School of Medicine \/ Washington University School of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Revimmune","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Glycosylated Recombinant Human Interleukin-7","moa":"IL-7 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Revimmune","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Revimmune"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Ocugen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"BBV154","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Washington University School of Medicine \/ Washington University School of Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Washington University School of Medicine \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Incyte Corporation | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Epacadostat","moa":"Indoleamine 2,3-dioxygenase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Incyte Corporation | National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ Incyte Corporation | National Cancer Institute"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"NeoImmuneTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"NT-I7","moa":"interleukins: interleukin-7 analogues and derivatives; Fc fusion protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ NeoImmuneTech","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ NeoImmuneTech"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Servier | Gateway for Cancer Research","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"Isocitrate dehydrogenase [NADP] cytoplasmic","graph1":"Hematology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Servier | Gateway for Cancer Research","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Servier | Gateway for Cancer Research"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Bristol Myers Squibb | Damon Runyon Cancer Research Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Enasidenib","moa":"Isocitrate dehydrogenase [NADP], mitochondrial","graph1":"Hematology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Bristol Myers Squibb | Damon Runyon Cancer Research Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Bristol Myers Squibb | Damon Runyon Cancer Research Foundation"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dimethyl Fumarate","moa":"Kelch-like ECH-associated protein 1","graph1":"Neurology","graph2":"Phase IV","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Biogen","highestDevelopmentStatusID":"11","companyTruncated":"Washington University School of Medicine \/ Biogen"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Children's Discovery Institute | Polaris Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Pegargiminase","moa":"L-arginine","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Washington University School of Medicine \/ Children's Discovery Institute | Polaris Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Children's Discovery Institute | Polaris Pharmaceuticals"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Polaris Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Pegargiminase","moa":"Arginase||L-arginine","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Washington University School of Medicine \/ Polaris Group","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ Polaris Group"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Polaris Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Pegargiminase","moa":"L-arginine","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Polaris Group","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ Polaris Group"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Amgen Inc | National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Leptin","moa":"Leptin receptor (LEPR)","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Amgen Inc | National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Washington University School of Medicine \/ Amgen Inc | National Institutes of Health"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"BASF","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2017","type":"Inapplicable","leadProduct":"Linoleic Acid","moa":"Lipid peroxidation","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ BASF","highestDevelopmentStatusID":"1","companyTruncated":"Washington University School of Medicine \/ BASF"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Daratumumab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Isatuximab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Sanofi"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Isatuximab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Sanofi"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Imago BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bomedemstat","moa":"||Lysine-specific histone demethylase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Washington University School of Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Pazopanib Hydrochloride","moa":"Macrophage colony stimulating factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Pazopanib Hydrochloride","moa":"Macrophage colony stimulating factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Pazopanib Hydrochloride","moa":"Macrophage colony stimulating factor receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"BioMed Valley Discoveries | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ulixertinib","moa":"MAP kinase ERK2 | MAP kinase ERK1","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ BioMed Valley Discoveries | National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ BioMed Valley Discoveries | National Cancer Institute"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"US Department of Defense | Aclaris Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Zunsemetinib","moa":"MAPKAPK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ US Department of Defense | Aclaris Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ US Department of Defense | Aclaris Therapeutics"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"National Cancer Institute | Aclaris Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Zunsemetinib","moa":"MAPKAPK2","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ National Cancer Institute | Aclaris Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ National Cancer Institute | Aclaris Therapeutics"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Hormone","year":"2016","type":"Inapplicable","leadProduct":"Corticotropin","moa":"Melanocortin receptor 2","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Mallinckrodt Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Washington University School of Medicine \/ Mallinckrodt Pharmaceuticals"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"E2814","moa":"||Microtubule-associated protein tau (MAPT)","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Washington University School of Medicine \/ Washington University School of Medicine","highestDevelopmentStatusID":"9","companyTruncated":"Washington University School of Medicine \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Alzheimer's Association | National Institute on Aging | Accelerating Medicines Partnership | Eisai Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"E2814","moa":"Microtubule-associated protein tau (MAPT)","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Alzheimer's Association | National Institute on Aging | Accelerating Medicines Partnership | Eisai Inc","highestDevelopmentStatusID":"9","companyTruncated":"Washington University School of Medicine \/ Alzheimer's Association | National Institute on Aging | Accelerating Medicines Partnership | Eisai Inc"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Eplerenone","moa":"Mineralocorticoid receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Pfizer Inc","highestDevelopmentStatusID":"11","companyTruncated":"Washington University School of Medicine \/ Pfizer Inc"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Pevonedistat","moa":"NEDD8 activating enzyme","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"Aprepitant","moa":"Neurokinin 1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Washington University School of Medicine \/ Washington University School of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Wugen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"CIML NK Cell","moa":"NK cell","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Washington University School of Medicine \/ Wugen","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Wugen"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"National Cancer Institute | Wugen | Children's Discovery Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"CIML NK Cell","moa":"NK cell","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Washington University School of Medicine \/ National Cancer Institute | Wugen | Children's Discovery Institute","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ National Cancer Institute | Wugen | Children's Discovery Institute"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Stanley Medical Research Institute | PPD","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Nitrous Oxide","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Washington University School of Medicine \/ Stanley Medical Research Institute | PPD","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Stanley Medical Research Institute | PPD"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"LifeCell","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Indocyanine Green","moa":"None","graph1":"Oncology","graph2":"Undisclosed","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ LifeCell","highestDevelopmentStatusID":"1","companyTruncated":"Washington University School of Medicine \/ LifeCell"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Reckitt Benckiser","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Venlafaxine","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Reckitt Benckiser","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ Reckitt Benckiser"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Good Ventures | Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Suvorexant","moa":"Orexin receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Good Ventures | Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Good Ventures | Merck & Co"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"National Institutes of Health | Eisai Inc | National Institute on Aging","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Lemborexant","moa":"Orexin receptor 1 | Orexin receptor 2","graph1":"Neurology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Washington University School of Medicine \/ National Institutes of Health | Eisai Inc | National Institute on Aging","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ National Institutes of Health | Eisai Inc | National Institute on Aging"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Precigen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"PRGN-3005","moa":"Ovarian carcinoma antigen CA125 (MUC16)","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Washington University School of Medicine \/ Washington University School of Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Merck & Co | Joseph Sanchez Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Merck & Co | Joseph Sanchez Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Merck & Co | Joseph Sanchez Foundation"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Tesaro","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Washington University School of Medicine \/ Tesaro","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Tesaro"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Merck & Co | Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Merck & Co | Ipsen","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Merck & Co | Ipsen"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Merck & Co"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Merck & Co"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ Merck & Co"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Merck & Co"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Merck & Co"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Arcus Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Zimberelimab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Arcus Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Arcus Biosciences"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Genentech"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Avelumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Pfizer Inc"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Foundation for Barnes-Jewish Hospital | Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Dalbavancin","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Foundation for Barnes-Jewish Hospital | Allergan","highestDevelopmentStatusID":"11","companyTruncated":"Washington University School of Medicine \/ Foundation for Barnes-Jewish Hospital | Allergan"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Omega-3-Acid Ethyl Esters 90","moa":"Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor alpha; Sterol regulatory element-binding protein 1","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ GSK","highestDevelopmentStatusID":"1","companyTruncated":"Washington University School of Medicine \/ GSK"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2017","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Celgene Corporation"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Verastem Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Duvelisib","moa":"PI3-kinase p110-gamma subunit | PI3-kinase p110-delta subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Washington University School of Medicine \/ Verastem Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Verastem Oncology"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"SecuraBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Duvelisib","moa":"PI3-kinase p110-gamma subunit | PI3-kinase p110-delta subunit","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ SecuraBio","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ SecuraBio"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"SecuraBio | Foundation for Barnes-Jewish Hospital | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Duvelisib","moa":"PI3-kinase p110-gamma subunit | PI3-kinase p110-delta subunit","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ SecuraBio | Foundation for Barnes-Jewish Hospital | National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ SecuraBio | Foundation for Barnes-Jewish Hospital | National Cancer Institute"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"AOSpine North America","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ AOSpine North America","highestDevelopmentStatusID":"9","companyTruncated":"Washington University School of Medicine \/ AOSpine North America"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Harvest Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2014","type":"Inapplicable","leadProduct":"Bone Marrow Aspirate Concentrate","moa":"Progenitor cell","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Harvest Technologies","highestDevelopmentStatusID":"1","companyTruncated":"Washington University School of Medicine \/ Harvest Technologies"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Durvalumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Washington University School of Medicine \/ MedImmune","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ MedImmune"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Durvalumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ AstraZeneca"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"MedImmune | National Cancer Institute | National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Durvalumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ MedImmune | National Cancer Institute | National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ MedImmune | National Cancer Institute | National Institutes of Health"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Durvalumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ AstraZeneca"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Novocure","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Novocure","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Novocure"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Bristol Myers Squibb | Prostate Cancer Foundation | Foundation for Barnes-Jewish Hospital | Bavarian Nordic","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"Rilimogene Galvacirepvec","moa":"Prostate specific antigen (KLK3)","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Bristol Myers Squibb | Prostate Cancer Foundation | Foundation for Barnes-Jewish Hospital | Bavarian Nordic","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Bristol Myers Squibb | Prostate Cancer Foundation | Foundation for Barnes-Jewish Hospital | Bavarian Nordic"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"University of Ghana | Arla Foods","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Protein","moa":"Protein","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ University of Ghana | Arla Foods","highestDevelopmentStatusID":"1","companyTruncated":"Washington University School of Medicine \/ University of Ghana | Arla Foods"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"National Cancer Institute | Verastem Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Defactinib","moa":"Protein tyrosine kinase 2 beta | Focal adhesion kinase 1","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ National Cancer Institute | Verastem Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ National Cancer Institute | Verastem Oncology"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Foundation for Barnes-Jewish Hospital | Merck & Co | Verastem Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Defactinib","moa":"Protein tyrosine kinase 2 beta | Focal adhesion kinase 1","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Foundation for Barnes-Jewish Hospital | Merck & Co | Verastem Oncology","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Foundation for Barnes-Jewish Hospital | Merck & Co | Verastem Oncology"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Verastem Oncology | Foundation for Barnes-Jewish Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Defactinib","moa":"Protein tyrosine kinase 2 beta | Focal adhesion kinase 1","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Verastem Oncology | Foundation for Barnes-Jewish Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Verastem Oncology | Foundation for Barnes-Jewish Hospital"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Puma Biotechnology | US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Neratinib","moa":"Receptor protein-tyrosine kinase erbB-4 | Epidermal growth factor receptor erbB1 | Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Puma Biotechnology | US Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Puma Biotechnology | US Department of Defense"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Curis | Foundation for Barnes-Jewish Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CA-4948","moa":"Renal carcinoma antigen NY-REN-64 (IRAK-4)","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Curis | Foundation for Barnes-Jewish Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Curis | Foundation for Barnes-Jewish Hospital"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Curis | Washington University Siteman Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"CA-4948","moa":"Renal carcinoma antigen NY-REN-64 (IRAK-4)","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Curis | Washington University Siteman Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Curis | Washington University Siteman Cancer Center"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Viewray Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Capecitabine","moa":"RNA | DNA | Thymidylate synthase","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Viewray Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Viewray Inc."},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ChAd-SARS-CoV-2-S","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Washington University School of Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Bharat Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Bharat Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Washington University School of Medicine \/ Bharat Biotech"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Bharat Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ChAd36-SARS-CoV-S","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Washington University School of Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Washington University School of Medicine \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"GlycoMimetics | Foundation for Barnes-Jewish Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Uproleselan","moa":"Selectin E","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ GlycoMimetics | Foundation for Barnes-Jewish Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ GlycoMimetics | Foundation for Barnes-Jewish Hospital"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Queen's University | Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Queen's University | Takeda Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Washington University School of Medicine \/ Queen's University | Takeda Pharmaceutical"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Bristol Myers Squibb | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Elotuzumab","moa":"SLAM family member 7","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Bristol Myers Squibb | Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Bristol Myers Squibb | Bristol Myers Squibb"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Novartis Pharmaceuticals Corporation | National Institutes of Health | National Institute of Diabetes and Digestive and Kidney Diseases | The University of Pittsburgh School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Carbamazepine","moa":"Sodium channel alpha subunit","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Novartis Pharmaceuticals Corporation | National Institutes of Health | National Institute of Diabetes and Digestive and Kidney Diseases | The University of Pittsburgh School of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Novartis Pharmaceuticals Corporation | National Institutes of Health | National Institute of Diabetes and Digestive and Kidney Diseases | The University of Pittsburgh School of Medicine"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"University of Texas System | Gateway Biotechnology | US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Zonisamide","moa":"Sodium channel alpha subunit","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Washington University School of Medicine \/ University of Texas System | Gateway Biotechnology | US Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ University of Texas System | Gateway Biotechnology | US Department of Defense"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"US Department of Defense | University of Texas System | Gateway Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Zonisamide","moa":"Sodium channel alpha subunit","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Washington University School of Medicine \/ US Department of Defense | University of Texas System | Gateway Biotechnology","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ US Department of Defense | University of Texas System | Gateway Biotechnology"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Cilgavimab","moa":"||Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Washington University School of Medicine \/ Washington University School of Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Washington University School of Medicine \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Mosunetuzumab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Genentech","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Genentech"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Genentech | Institute for Follicular Lymphoma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Mosunetuzumab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Genentech | Institute for Follicular Lymphoma","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Genentech | Institute for Follicular Lymphoma"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Mosunetuzumab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Genentech","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Genentech"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"MacroGenics | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Flotetuzumab","moa":"T cell surface glycoprotein CD3 | Interleukin-3 receptor subunit alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Washington University School of Medicine \/ MacroGenics | National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ MacroGenics | National Cancer Institute"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"18-F RO-948","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2019","type":"Inapplicable","leadProduct":"Fluorouracil","moa":"RNA | DNA | Thymidylate synthase||Thymidylate synthase | RNA | DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Ipsen","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Ipsen"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"National Heart, Lung, and Blood Institute | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Belatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ National Heart, Lung, and Blood Institute | Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ National Heart, Lung, and Blood Institute | Bristol Myers Squibb"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Washington University School of Medicine \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Merck & Co"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"National Institutes of Health | National Cancer Institute | Breast Cancer Research Foundation | NeoImmuneTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ National Institutes of Health | National Cancer Institute | Breast Cancer Research Foundation | NeoImmuneTech","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ National Institutes of Health | National Cancer Institute | Breast Cancer Research Foundation | NeoImmuneTech"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2015","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Sanofi"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Celgene Corporation"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2015","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Celgene Corporation"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2018","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Neurology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"National Cancer Institute | Aravive","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ National Cancer Institute | Aravive","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ National Cancer Institute | Aravive"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"GSK | American Cancer Society","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Belimumab","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ GSK | American Cancer Society","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ GSK | American Cancer Society"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"National Comprehensive Cancer Network | Pfizer Inc | Rapid Novor","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Elranatamab","moa":"Tumor necrosis factor receptor superfamily member 17 | T cell surface glycoprotein CD3","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ National Comprehensive Cancer Network | Pfizer Inc | Rapid Novor","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ National Comprehensive Cancer Network | Pfizer Inc | Rapid Novor"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Celldex Therapeutics | Foundation for Barnes-Jewish Hospital | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"CDX-1140","moa":"Tumor necrosis factor receptor superfamily member 5","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Celldex Therapeutics | Foundation for Barnes-Jewish Hospital | National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Celldex Therapeutics | Foundation for Barnes-Jewish Hospital | National Cancer Institute"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2012","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"Tumor necrosis factor receptor superfamily member 8 | Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Pfizer Inc"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Bristol Myers Squibb | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2014","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"Tumor necrosis factor receptor superfamily member 8 | Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Bristol Myers Squibb | Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Bristol Myers Squibb | Pfizer Inc"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Apollomics Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"APL-101","moa":"tyrosine kinase inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Apollomics Inc","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ Apollomics Inc"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"UConn Health","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dasatinib","moa":"Tyrosine-protein kinase ABL | Bcr\/Abl fusion protein | Platelet-derived growth factor receptor beta | Ephrin type-A receptor 2 | SRC | Stem cell growth factor receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ UConn Health","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ UConn Health"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Pharmacyclics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Pharmacyclics","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Pharmacyclics"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Incyte Corporation | American Society of Hematology | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Itacitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Incyte Corporation | American Society of Hematology | National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Incyte Corporation | American Society of Hematology | National Cancer Institute"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Washington University School of Medicine \/ Incyte Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Incyte Corporation"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Washington University School of Medicine \/ Incyte Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Washington University School of Medicine \/ Incyte Corporation"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Incyte Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Incyte Corporation"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Eli Lilly"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Pacritinib","moa":"Tyrosine-protein kinase receptor FLT3 | Tyrosine-protein kinase JAK2","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Pacritinib","moa":"Tyrosine-protein kinase receptor FLT3 | Tyrosine-protein kinase JAK2","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Pacritinib","moa":"Tyrosine-protein kinase receptor FLT3 | Tyrosine-protein kinase JAK2","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Rigel Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fostamatinib","moa":"Tyrosine-protein kinase SYK","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Washington University School of Medicine \/ Rigel Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Rigel Pharmaceuticals"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Cellect Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Apograft","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Cellect Biotechnology","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Cellect Biotechnology"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Aclaris Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ATI-2231","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Aclaris Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Aclaris Therapeutics"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Quest Medical, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Cardioplexol","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Washington University School of Medicine \/ Quest Medical, Inc","highestDevelopmentStatusID":"11","companyTruncated":"Washington University School of Medicine \/ Quest Medical, Inc"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Arla Foods | Kamuzu University of Health Sciences | Project Peanut Butter","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Dietary Supplement","year":"2018","type":"Inapplicable","leadProduct":"C-RUSF","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Arla Foods | Kamuzu University of Health Sciences | Project Peanut Butter","highestDevelopmentStatusID":"1","companyTruncated":"Washington University School of Medicine \/ Arla Foods | Kamuzu University of Health Sciences | Project Peanut Butter"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Project Peanut Butter | Kamuzu University of Health Sciences | Balchem Corp","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"C-RUSF","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Project Peanut Butter | Kamuzu University of Health Sciences | Balchem Corp","highestDevelopmentStatusID":"1","companyTruncated":"Washington University School of Medicine \/ Project Peanut Butter | Kamuzu University of Health Sciences | Balchem Corp"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Centers for Disease Control and Prevention | University of Pennsylvania | Duke University | Rush University | Rebiotix","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2017","type":"Inapplicable","leadProduct":"Fecal Microbiota","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Enema","sponsorNew":"Washington University School of Medicine \/ Centers for Disease Control and Prevention | University of Pennsylvania | Duke University | Rush University | Rebiotix","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ Centers for Disease Control and Prevention | University of Pennsylvania | Duke University | Rush University | Rebiotix"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Geneos Therapeutics | Foundation for Barnes-Jewish Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"GNOS-PV01","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Geneos Therapeutics | Foundation for Barnes-Jewish Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Geneos Therapeutics | Foundation for Barnes-Jewish Hospital"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"The Task Force for Global Health | Murdoch Childrens Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"IDA","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Cream","sponsorNew":"Washington University School of Medicine \/ The Task Force for Global Health | Murdoch Childrens Research Institute","highestDevelopmentStatusID":"1","companyTruncated":"Washington University School of Medicine \/ The Task Force for Global Health | Murdoch Childrens Research Institute"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"COVID-19 Therapeutics Accelerator","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Measles, Mumps And Rubella Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ COVID-19 Therapeutics Accelerator","highestDevelopmentStatusID":"10","companyTruncated":"Washington University School of Medicine \/ COVID-19 Therapeutics Accelerator"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Project Peanut Butter | Ministry of Health and Sanitation, Sierra Leone | Arla Foods Ingredients | The Danish Dairy Research Foundation, Denmark","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"MFGM-RUTF","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Project Peanut Butter | Ministry of Health and Sanitation, Sierra Leone | Arla Foods Ingredients | The Danish Dairy Research Foundation, Denmark","highestDevelopmentStatusID":"1","companyTruncated":"Washington University School of Medicine \/ Project Peanut Butter | Ministry of Health and Sanitation, Sierra Leone | Arla Foods Ingredients | The Danish Dairy Research Foundation, Denmark"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"AstraZeneca | Gateway for Cancer Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Neoantigen DNA Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Washington University School of Medicine \/ AstraZeneca | Gateway for Cancer Research","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ AstraZeneca | Gateway for Cancer Research"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"National Cancer Institute | Leidos | UNICO Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Neoantigen Synthetic Long Peptide Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ National Cancer Institute | Leidos | UNICO Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ National Cancer Institute | Leidos | UNICO Foundation"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2018","type":"Inapplicable","leadProduct":"Neoantigen-Based Personalized Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Washington University School of Medicine \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Incyte Corporation | PapiVax Biotech | Foundation for Barnes-Jewish Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Personalized Neoantigen Dna Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Incyte Corporation | PapiVax Biotech | Foundation for Barnes-Jewish Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Incyte Corporation | PapiVax Biotech | Foundation for Barnes-Jewish Hospital"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"ACCESS Community Health Network | University of Sydney","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Quartet","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ ACCESS Community Health Network | University of Sydney","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ ACCESS Community Health Network | University of Sydney"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"NeoImmuneTech | Foundation for Barnes-Jewish Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Recombinant Human IL-7-hyFc","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Washington University School of Medicine \/ NeoImmuneTech | Foundation for Barnes-Jewish Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ NeoImmuneTech | Foundation for Barnes-Jewish Hospital"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Recombinant Human Interleukin-7","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Washington University School of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Natera","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Synthetic Long Peptide Personalized Cancer Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Natera","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Natera"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"VSV-SARS-CoV-2 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Washington University School of Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"Vascular endothelial growth factor A","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Washington University School of Medicine \/ Incyte Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Incyte Corporation"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Aflibercept","moa":"Vascular endothelial growth factor A | Placenta growth factor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Washington University School of Medicine \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lenvatinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Merck & Co"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Exelixis","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Exelixis"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Exelixis | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Exelixis | Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Exelixis | Bristol Myers Squibb"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Bristol Myers Squibb | Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Undisclosed","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Bristol Myers Squibb | Exelixis","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Bristol Myers Squibb | Exelixis"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Ramucirumab","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Eli Lilly"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Eli Lilly | ImmunityBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Ramucirumab","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Eli Lilly | ImmunityBio","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Eli Lilly | ImmunityBio"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Ramucirumab","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Eli Lilly"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Ramucirumab","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ Eli Lilly"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"VEGFR2","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Exelixis","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Exelixis"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"National Cancer Institute | Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"VEGFR2","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ National Cancer Institute | Exelixis","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ National Cancer Institute | Exelixis"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"VEGFR2","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Exelixis","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Exelixis"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"VEGFR2","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Exelixis","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Exelixis"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Sensei Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Collaboration","leadProduct":"SNS-101","moa":"VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Washington University School of Medicine \/ Washington University School of Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Acorda Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Fampridine","moa":"Voltage-gated potassium channel","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Washington University School of Medicine \/ Acorda Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"Washington University School of Medicine \/ Acorda Therapeutics"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Washington University School of Medicine","highestDevelopmentStatusID":"2","companyTruncated":"Washington University School of Medicine \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"BostonGene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Washington University School of Medicine \/ Washington University School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Washington University School of Medicine \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"AssureRx Health","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ AssureRx Health","highestDevelopmentStatusID":"11","companyTruncated":"Washington University School of Medicine \/ AssureRx Health"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase IV","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Washington University School of Medicine \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Abbott Laboratories | Biomerieux","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase IV","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Abbott Laboratories | Biomerieux","highestDevelopmentStatusID":"11","companyTruncated":"Washington University School of Medicine \/ Abbott Laboratories | Biomerieux"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Biosplice","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Cirtuvivint","moa":"CLK|DYRK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Biosplice","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ Biosplice"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Influenza Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"Washington University School of Medicine \/ AstraZeneca"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"NeoImmuneTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Recombinant Human IL-7","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ NeoImmuneTech","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ NeoImmuneTech"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Karyopharm Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Selinexor","moa":"Exportin-1","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Karyopharm Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Karyopharm Therapeutics"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Insignis Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"L-Dipivefrin","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Washington University School of Medicine \/ Washington University School of Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Washington University School of Medicine"}]

    Find Clinical Drug Pipeline Developments & Deals by Washington University School of Medicine

    Menu

    Washington University School of Medicine

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Washington University School of Medicine

                            U.S.A arrow
                            Aquaexpo
                            Not Confirmed

                            Washington University School of Medicine

                            U.S.A arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : L-Dipivefrin

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Recipient : Insignis Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PK/PD Study of IN-001 Sublingual Spray in Healthy Adults

                            Details : L-Dipivefrin is a small molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Hypersensitivity.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 07, 2025

                            Lead Product(s) : L-Dipivefrin

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Recipient : Insignis Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Washington University School of Medicine

                            U.S.A arrow
                            Aquaexpo
                            Not Confirmed

                            Washington University School of Medicine

                            U.S.A arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cirtuvivint

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Biosplice

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)

                            Details : Cirtuvivint is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Small Cell Lung Carcinoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 04, 2025

                            Lead Product(s) : Cirtuvivint

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Biosplice

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Washington University School of Medicine

                            U.S.A arrow
                            Aquaexpo
                            Not Confirmed

                            Washington University School of Medicine

                            U.S.A arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Defactinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Verastem Oncology | Foundation for Barnes-Jewish Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Radiotherapy Plus FAK & RAF/MEK Inhibitors in Advanced Pancreatic Adenocarcinoma

                            Details : Defactinib is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Pancreatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 17, 2025

                            Lead Product(s) : Defactinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Verastem Oncology | Foundation for Barnes-Jewish Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Washington University School of Medicine

                            U.S.A arrow
                            Aquaexpo
                            Not Confirmed

                            Washington University School of Medicine

                            U.S.A arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HT-ALZ

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Recipient : Hoth Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Hoth, WashU Advance Alzheimer's Program with NK-1 Antagonist HT-ALZ

                            Details : The collaboration aims to advance the clinical development of HT-ALZ, which is being evaluated for the treatment of Alzheimer's disease.

                            Product Name : HT-ALZ

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            April 02, 2025

                            Lead Product(s) : HT-ALZ

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Recipient : Hoth Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Washington University School of Medicine

                            U.S.A arrow
                            Aquaexpo
                            Not Confirmed

                            Washington University School of Medicine

                            U.S.A arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MFGM-RUTF

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Undisclosed

                            Sponsor : Project Peanut Butter | Ministry of Health and Sanitation, Sierra Leone | Arla Foods Ingredients | The Danish Dairy Research Foundation, Denmark

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Milk Fat Globule Membrane-Enhanced RUTF for Children With Severe Acute Malnutrition

                            Details : MFGM-RUTF is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Severe Acute Malnutrition.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            March 11, 2025

                            Lead Product(s) : MFGM-RUTF

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Undisclosed

                            Sponsor : Project Peanut Butter | Ministry of Health and Sanitation, Sierra Leone | Arla Foods Ingredients | The Danish Dairy Research Foundation, Denmark

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Washington University School of Medicine

                            U.S.A arrow
                            Aquaexpo
                            Not Confirmed

                            Washington University School of Medicine

                            U.S.A arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azeliragon

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Cantex Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblast...

                            Details : Azeliragon is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Glioblastoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 18, 2025

                            Lead Product(s) : Azeliragon

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Cantex Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Washington University School of Medicine

                            U.S.A arrow
                            Aquaexpo
                            Not Confirmed

                            Washington University School of Medicine

                            U.S.A arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zunsemetinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : National Cancer Institute | Aclaris Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma

                            Details : Zunsemetinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Pancreatic Ductal.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 18, 2024

                            Lead Product(s) : Zunsemetinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : National Cancer Institute | Aclaris Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Washington University School of Medicine

                            U.S.A arrow
                            Aquaexpo
                            Not Confirmed

                            Washington University School of Medicine

                            U.S.A arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Remternetug

                            Therapeutic Area : Neurology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Alzheimer's Association | Eli Lilly | National Institute on Aging | GHR Foundation | Private Donors

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD...

                            Details : Remternetug is a Antibody drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            October 17, 2024

                            Lead Product(s) : Remternetug

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Alzheimer's Association | Eli Lilly | National Institute on Aging | GHR Foundation | Private Donors

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Washington University School of Medicine

                            U.S.A arrow
                            Aquaexpo
                            Not Confirmed

                            Washington University School of Medicine

                            U.S.A arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DSP-0390

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Sumitomo Pharma America

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Window of Opportunity Study of DSP-0390 in Gliomas

                            Details : DSP-0390 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Glioma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 10, 2024

                            Lead Product(s) : DSP-0390

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Sumitomo Pharma America

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Washington University School of Medicine

                            U.S.A arrow
                            Aquaexpo
                            Not Confirmed

                            Washington University School of Medicine

                            U.S.A arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Motixafortide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : BioLineRx | Arvrmid Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Follow...

                            Details : Motixafortide is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Multiple Myeloma.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            August 09, 2024

                            Lead Product(s) : Motixafortide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : BioLineRx | Arvrmid Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth